These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2049 related articles for article (PubMed ID: 28154958)
1. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction. Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958 [TBL] [Abstract][Full Text] [Related]
2. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609 [TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458 [TBL] [Abstract][Full Text] [Related]
4. NT-ProBNP and hsTnI: A Multistate Survival Analysis in Outpatients with Reduced Left-Ventricular Ejection Fraction. Di Gesaro G; Caccamo G; Bellavia D; Falletta C; Minà C; Romano G; Agnese V; Tuzzolino F; Clemenza F Cardiology; 2019; 142(1):7-13. PubMed ID: 30852580 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction. Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719 [TBL] [Abstract][Full Text] [Related]
6. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848 [TBL] [Abstract][Full Text] [Related]
7. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP; Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH; Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121 [TBL] [Abstract][Full Text] [Related]
9. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640 [TBL] [Abstract][Full Text] [Related]
10. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866 [TBL] [Abstract][Full Text] [Related]
11. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842 [TBL] [Abstract][Full Text] [Related]
12. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053 [TBL] [Abstract][Full Text] [Related]
13. Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study). Seliger SL; de Lemos J; Neeland IJ; Christenson R; Gottdiener J; Drazner MH; Berry J; Sorkin J; deFilippi C JACC Heart Fail; 2015 Jun; 3(6):445-455. PubMed ID: 25982111 [TBL] [Abstract][Full Text] [Related]
14. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760 [TBL] [Abstract][Full Text] [Related]
15. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. Pellicori P; Carubelli V; Zhang J; Castiello T; Sherwi N; Clark AL; Cleland JG JACC Cardiovasc Imaging; 2013 Jan; 6(1):16-28. PubMed ID: 23328557 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Utility of Troponin I and N Terminal-ProBNP among Patients with Heart Failure due to Non-Ischemic Cardiomyopathy and Important Correlations. Mene-Afejuku TO; Dumancas C; Akinlonu A; Ola O; Cativo EH; Veranyan S; Lopez PD; Kim KS; Pekler G; Mushiyev S; Visco F Cardiovasc Hematol Agents Med Chem; 2019; 17(2):94-103. PubMed ID: 31875779 [TBL] [Abstract][Full Text] [Related]
17. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure. Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583 [TBL] [Abstract][Full Text] [Related]
19. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors. Suzuki S; Sugiyama S Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934 [TBL] [Abstract][Full Text] [Related]
20. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]